Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07775456
Active, not recruiting Phase 2

Evaluation of Postoperative Pain and Bacterial Load After Hyalone or Calcium Hydroxide Medication in Mandibular First Molars

NCT07775456 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2
Started
2026-06-01
Last updated
2026-08-20

Condition(s) studied

Bacterial Load ReductionPostoperative Pain

Investigational drug(s) / intervention(s)

Hyalone →Calcium Hydroxide (Ca(OH)2) Intracanal Medication →

Hyalone: Group I (Hyalone® gel): Hyaluronic acid gel (Hyalone®) was delivered using a sterile 3-mL disposable syringe fitted with a flexible 30-gauge endodontic NaviTip.

Calcium Hydroxide (Ca(OH)2) Intracanal Medication: Group II (MetaPaste®): Calcium hydroxide paste (MetaPaste®, Meta Biomed, Chungcheongbuk-do, Republic of Korea) was delivered using the manufacturer's preloaded syringe fitted with a disposable intracanal delivery tip.

Study summary

This randomized controlled clinical trial aims to evaluate the effect of Hyalone hydrogel compared with calcium hydroxide as an intracanal medicament on postoperative pain and bacterial load reduction in mandibular first molars with necrotic pulp and symptomatic apical periodontitis. The rationale for the study is based on the important role of intracanal medicaments in reducing residual microorganisms between treatment appointments. Calcium hydroxide is widely used because of its antimicrobial activity and alkaline pH; however, it has limitations related to its distribution, adherence to canal walls, antimicrobial spectrum, and effectiveness against microorganisms in complex root canal anatomy. Hyaluronic acid hydrogel has demonstrated potential benefits in dentistry, including supporting tissue healing and reducing inflammation and pain, and may therefore represent a promising alternative intracanal medicament.

The study will include 28 patients, equally divided into two groups of 14 participants. Patients will be recruited from the Endodontic Department outpatient clinic at the Faculty of Oral and Dental Medicine, Future University in Egypt. Eligible participants will be medically healthy patients aged 20-40 years, with mandibular first molars diagnosed with necrotic pulp and symptomatic apical periodontitis. Teeth should have closed apices, be restorable, be sensitive to percussion, and demonstrate slight widening of the lamina dura radiographically. Patients with systemic diseases, pregnancy or lactation, allergies to study medications, recent use of antibiotics or analgesics, swelling or acute apical abscess, open apices, vital pulp, periodontal mobility, previous root canal treatment, or abnormal/calcified canal anatomy will be excluded.

All participants will receive standardized endodontic treatment over two visits. During the first visit, medical and dental histories, clinical examination, radiographic examination, and preoperative pain assessment using the Numerical Rating Scale (NRS) will be performed. Following local anesthesia, caries removal, access cavity preparation, and rubber dam isolation, working length will be determined using an electronic apex locator and confirmed radiographically. The initial bacteriological sample (S1) will then be collected using sterile #15 paper points placed in the canal for one minute each. The samples will be processed microbiologically, and bacterial counts will be expressed as colony-forming units per milliliter (CFU/mL).

Cleaning and shaping will then be performed using a crown-down rotary instrumentation technique, with sterile saline irrigation between instruments. Following completion of instrumentation, a second bacteriological sample (S2) will be obtained to determine the reduction in bacterial load resulting from chemomechanical preparation. Patients will subsequently receive either Hyalone or calcium hydroxide, according to their randomized allocation. The medicament will be placed under aseptic conditions, and the access cavity will be temporarily restored using glass ionomer.

At the second visit after 7 days, the temporary restoration and intracanal medicament will be removed. The canals will be irrigated with sterile saline and a third bacteriological sample (S3) will be collected. This sample will allow assessment of the additional bacterial reduction associated with the intracanal medicament. Following sampling, the canals will be irrigated with 2.5% sodium hypochlorite and obturated using the cold lateral condensation technique with gutta-percha and resin sealer. The teeth will then receive a final composite restoration.

The primary outcome of the study is postoperative pain. Pain will be recorded using an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as could be). Patients will record their pain preoperatively and at 6, 12, 24, 48, and 72 hours and one week following treatment. Pain scores will also be categorized as none, mild, moderate, or severe.

The secondary outcome is the antimicrobial effect of the two intracanal medicaments. Bacterial samples obtained at S1, S2, and S3 will be analyzed using the serial dilution technique, with bacterial counts expressed as CFU/mL. Samples will be processed under aerobic and anaerobic conditions to assess the cultivable bacterial population. The changes in bacterial load before instrumentation, after chemomechanical preparation, and after intracanal medication will then be compared.

The sample size was calculated based on a previous study, with a minimum required sample of 11 participants per group. The number was increased to 14 participants

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion criteria: Medically free patients with no systemic disease: (American Society of Anesthesiologists / (ASA Class I or II). Positive patient acceptance for participating in the study. Patients able to sign informed consent. Age range is between 20 to 40 years. No sex predilection. Mandibular first molars teeth with necrotic pulp and symptomatic apical periodontitis. Type l distal root canal (Vertucci classification). Teeth Sensitive to percussion. Teeth with Periapical radiographic appearance showing slight widening in lamina dura. Restorable teeth. B- Exclusion criteria: Medically compromised patients. Pregnant or lactating females. Psychologically disturbed patients. Patients with a history of allergy to any medication used in the study were excluded. If anti-inflammatory analgesics or antibiotics have been administrated by patient during the past 12 hours preoperatively. Patients with swelling or acute peri-apical abscess or fistulous tract. Teeth that have: Wide or open apex. Vital pulp tissues. affected with grade 2 or 3 mobility. Not restorable teeth.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Future University In Egypt Cairo Egypt

More Future University in Egypt trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07775456 on ClinicalTrials.gov ↗ ← All trials in Egypt